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To  develop  a  novel  enzyme  replacement  therapy  for 
neurodegenerative Tay-Sachs disease (TSD) and Sand-
hoff  disease  (SD),  which  are  caused  by  deficiency  of 
β-hexosaminidase  (Hex)  A,  we  designed  a  geneti-
cally  engineered  HEXB  encoding  the  chimeric  human 
β-subunit containing partial amino acid sequence of the 
α-subunit by structure-based homology modeling. We 
succeeded in producing the modified HexB by a Chi-
nese  hamster  ovary  (CHO)  cell  line  stably  expressing 
the chimeric HEXB, which can degrade artificial anionic 
substrates and GM2 ganglioside in vitro, and also retain 
the wild-type (WT) HexB-like thermostability in the pres-
ence of plasma. The modified HexB was efficiently incor-
porated via cation-independent mannose 6-phosphate 
receptor into fibroblasts derived from Tay-Sachs patients, 
and reduced the GM2 ganglioside accumulated in the 
cultured  cells.  Furthermore,  intracerebroventricular 
administration of the modified HexB to Sandhoff mode 
mice restored the Hex activity in the brains, and reduced 
the GM2 ganglioside storage in the parenchyma. These 
results suggest that the intracerebroventricular enzyme 
replacement therapy involving the modified HexB should 
be more effective for Tay-Sachs and Sandhoff than that 
utilizing the HexA, especially as a low-antigenic enzyme 
replacement therapy for Tay-Sachs patients who have 
endogenous WT HexB.
Received 14 October 2010; accepted 27 January 2011; published online 
12 April 2011. doi:10.1038/mt.2011.27
IntroductIon
Tay-Sachs disease (TSD) and Sandhoff disease (SD) are neurode-
generative GM2 gangliosidoses caused by mutations in the HEXA 
and HEXB genes encoding the α- and β-subunits of human lyso-
somal β-hexosaminidase (Hex) (EC 3.2.1.52), respectively. They 
involve HexA (αβ-heterodimer) deficiency, lysosomal accumula-
tion of GM2, mainly in neural tissues, and neurological symptoms.1,2 
There are two major Hex isozymes, HexB (ββ-homodimer) and 
HexA,  in  mammals.  Thermostable  HexB  can  degrade  neutral 
substrates, whereas HexA can cleave both neutral and anionic 
substrates, although only HexA can degrade GM2 in cooperation 
with GM2 activator protein (GM2AP).
So far, little effective treatment for these GM2 gangliosidoses 
has been developed, although several experimental and clinical 
trials have been performed.3–6 In recent years, intravenous enzyme 
replacement therapy (ERT) involving recombinant enzyme drugs 
produced by mammalian cell lines stably expressing human lyso-
somal enzyme genes has been clinically applied for lysosomal stor-
age diseases (LSDs), including Gaucher disease,7,8 Fabry disease,9 
Pompe disease,10,11 and mucopolysaccharidoses I,12 and II13 involv-
ing peripheral dysfunctions such as hepatosplenomegaly, vascular 
disorders,  cardiomegaly,  and  dysostosis  multiplex.  Intravenous 
ERT is based on incorporation of a recombinant enzyme via cell 
surface glycan receptors, including MR7,8 and CI-M6PR/insulin-
like growth factor type II receptor,9–13 into the target organs, and 
delivery to intracellular lysosomes and degradation of the accu-
mulated substrates. However, intravenous ERT is ineffective for 
LSD patients with neurological symptoms because of the presence 
of the blood brain barrier, although delivery through the cere-
brospinal fluid as a potential route to the central nervous system 
has been examined to develop intracerebroventricular (icv) and 
intrathecal ERT for LSD patients with the central nervous system 
affected.14–16 In addition to above issues, enzyme functions, includ-
ing substrate preference, efficiency of uptake and maintenance of 
intracellular catalytic activity, are important factors for therapeu-
tic  effectiveness  on  intravenous  and  icv  ERT.  Furthermore,  an 
adverse outcome of intravenous ERT, immune responses to thera-
peutic enzymes due to the production of neutralizing antibodies 
in LSD patients, has been reported.17 For example, such neutral-
izing antibodies abrogate the therapeutic effect in Pompe disease 
patients.11
In this study, we designed and developed a modified HexB 
with GM2-degrading activity and binding ability as to GM2AP, 
based on the amino acid sequence homology between the Hex 
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α-  and  β-subunits.  Here,  we  show  that  therapeutic  effects  of 
modified HexB of icv replacement for GM2 gangliosidosis model 
mouse. The modified HexB could be a potentially low-antigenic 
therapeutic enzyme for icv ERT for TSD patients who have an 
intrinsic Hex β-subunit.
results
structure-based design of a modified HexB β-subunit
A homology model of the modified human Hex β-subunit was 
built on the basis of the X-ray crystallographic data for the human 
Hex β-subunit (protein Databank code, 1now) and the amino acid 
sequence for human Hex α-subunit, which exhibits 56% amino 
acid identity with the human Hex β-subunit. In order to create a 
modified Hex β-subunit with an α-subunit-like substrate prefer-
ence and binding ability as to GM2AP, the difference in the sol-
vent accessible surface area value of each residue between the apo 
form of Hex β-subunit and its complex with the substrate analog 
inhibitor was calculated at first. As a result, 13 residues (R211, 
H237, D240, H294, D354, E355, W405, W424, Y450, D452, L453, 
W489, and E491) were defined as residues involved in the active 
pocket of β-subunit. Figure 1 shows structural comparison of the 
wild-type (WT) β- and modified β-subunits. Among the pocket 
residues, only D452 and L453 are not conserved in the α- and 
β-subunits, indicating that βD452 and βL453 are important as to 
determining the substrate specificity.
The  loop  (280-283,  GSEP)  sequence  in  the  α-subunit  is 
required for GM2AP to interact with HexA, and essential for the 
degradation of GM2 by HexA. In total, the functions of HexA 
including its binding ability as to GM2AP and substrate specificity 
may be due to these six residues (G280, S281, E282, P283, N423, 
and R424) of the α-subunit. Therefore, we replaced R312, Q313, 
N314, K315 (Figure 1c,d), D452 and L453 (Figure 1a,b) of the 
β-subunit with the corresponding residues, G, E, S, P, N, and R of 
the α-subunit, respectively, to change the substrate preference to 
anionic substrates and the binding ability as to GM2AP of the WT 
β-subunit, and thereby designed a modified β-subunit.
expression and purification of modified HexB  
with an altered substrate specificity and a loop 
sequence for interacting with GM2AP
Each of WTHEXB and the modified HEXB cDNA bearing the 
R312G, Q313S, N314E, K315P, D452N, and L453R substitutions 
in  the  β-subunit  was  introduced  into  Chinese  hamster  ovary 
(CHO) cells. The conditioned medium (CM) of each cell line 
was  collected,  and  the  recombinant  enzymes  were  purified  by 
three-step column chromatography. Figure 2a,b show the results 
obtained on native- and sodium dodecyl sulfate polyaclylamide 
gel electrophoresis, respectively. Modified HexB migrated to the 
same position as WTHexB, indicating that the molecular mass and 
electrostatic properties of the modified HexB were similar to those 
of WTHexB (Figure 2a). Figure 2b shows intracellular processing 
of β-subunit. The mature form of WT β-subunit is composed of 
three polypeptides and they are connected by disulfide bond. WT 
precursor β-subunit was detected at the 63 kDa and mature ones 
Leu 453 Asp 452
Arg 453 Asn 452
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Figure 1  structure of wild-type HexB (WtHexB) and modified HexB. (a,c) The active site and loop structure of WTHexB and (b,d) those of the modi-
fied HexB are shown as ribbon models. Each structure is presented as a complex with a substrate analog inhibitor. βD452 and βL453 are corresponding 
to αN423 and αR424, which are important for determining the substrate specificity. Green arrows indicate the position of the loop structure.Molecular Therapy  vol. 19 no. 6 june 2011  1019
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were detected at the 29, 23, and 21 kDa under the experimental 
condition, respectively. On the other hand, the major β-subunit 
moieties of modified HexB migrated to the 63 and 51 kDa, and 
minor ones migrated to the 29, 23, and 21 kDa, respectively. These 
results  indicate  different  processing  pattern  between  WT-  and 
modified β-subunit.
enzymological characteristics of modified HexB
The kinetic parameters for degradation of 4-methylumbelliferyl 
N-acetyl-β-D-glucosaminide (4-MUG) and 4-methylumbellifery-
6-sulfo-β-D-glucosaminide potassium salt (4-MUGS) of WT- and 
modified HexB were measured. The Km value for 4-MUG of the 
modified HexB was slightly decreased, whereas that for 4-MUGS 
was greatly decreased compared with those for WTHexB (Table 1). 
The  specific  activities  of  WT-  and  modified  HexB  toward  the 
4-MUG were 3.3 × 10−3 mmol/minute/mg protein and 1.5 × 10−3 
mmol/minute/mg protein, and those of WT- and modified HexB 
toward the 4-MUGS were 5.0 × 10−5 mmol/minute/mg protein 
and 5.0 × 10−3 mmol/minute/mg protein, respectively. The ther-
mostability of the modified HexB in murine plasma was examined 
in vitro. The modified HexB retained higher stability than that of 
WTHexB 7 days after incubation (Table 2).
GM2-degrading activity of modified HexB  
in vitro and in tsd fibroblasts
To examine the GM2-degrading activity of modified HexB, GM2 
micelles were incubated with Hex isozymes, followed by thin-layer 
chromatography. As shown in Figure 3a, modified HexB degraded 
GM2 in a similar manner as HexA, but there was no degradation 
of GM2 by WTHexB. Next, the effects of amino acid substitutions 
in  the  Hex  β-subunit  were  evaluated  on  enzyme  replacement 
in fibroblasts (F218) derived from a TSD patient. The WT- or 
modified HexB was added to the cultured medium, followed by 
incubation for 4 days. Then restoration of the Hex activity and 
reduction of the accumulated GM2 were examined with anti-GM2 
antibodies after treatment with the modified HexB by means of 
immunofluorescent microscopy. As shown in Figure 3b, signifi-
cant restoration of 4-MUGS-degrading activity was observed in 
TSD fibroblasts on treatment with the modified HexB, which was 
superior to WTHexA. The recovery of Hex activity on treatment 
with the modified HexB was significantly inhibited in the pres-
ence of 5 mmol/l M6P. These results indicate that the modified 
HexB was taken up via CI-M6PR. As shown in Figure 3c, remark-
able accumulation of GM2 due to HexA deficiency was detected 
in the TSD fibroblasts. WTHexA reduced the accumulated GM2. 
The modified HexB also degraded GM2, although no reduction 
was observed in the TSD fibroblasts on treatment with WTHexB. 
There seemed to be little difference in GM2-degrading activity 
between the modified HexB and WTHexA. The reduction of GM2 
was also inhibited in presence of 5 mmol/l M6P, indicating that 
uptake of the modified HexB carrying M6P-type N-glycans was 
mediated by CI-M6PR.
replacement effects of the modified  
HexB on sandhoff mice
The replacement effects of modified HexB on icv injection into 
the lateral cerebral ventricles of 10-week-old SD mice were further 
examined. One week after injection of the modified HexB, the Hex 
activity (4-MUGS) in each region (fore-, mid-, and hindbrain) of 
SD mice had recovered to above 40% of that observed in the WT 
mice. Three weeks after injection, the residual Hex activity was 
maintained at above 15% of the level in the WT mice, it being 
especially about 40% in the hindbrain of SD mice (Figure 4a). The 
effect of icv administration of modified HexB on the recovery of 
the Hex activity was greater than that of WTHexA (Figure 3b and 
Supplementary Figure S1).
The effects of icv administration of the modified HexB on 
reduction of the accumulated substrates in the brain regions of 
SD mice were also analyzed by immunohistochemistry 3 weeks 
H
e
x
A
H
e
x
B
M
o
d
i
f
i
e
d
W
T
H
e
x
B
Anti-HexA
WT/modified
HexA
HexB
Anti-HexA
M WT   Modified
60 kDa
63 kDa
29 kDa
23 kDa
21 kDa
51 kDa 50 kDa
40 kDa
30 kDa
ab
Figure 2  Immunoblotting of the Hex isozyme. (a) The native form of 
the modified HexB, wild-type HexB (WTHexB) and HexA were separated 
by native-polyacrylamide gel electrophoresis (PAGE), and (b) the WT- 
and modified HexB were separated by sodium dodecyl sulfate-PAGE, and 
then immunoblotting analysis with anti-HexA antibodies was performed. 
Each lane contained 750 nmol/hour 4-methylumbelliferyl N-acetyl-β-D-
glucosaminide (4-MUG)-degrading activity.
table 1  Kinetic parameters of Hex isozymes
enzyme
4-MuG 4-MuGs
specific 
activity Km/Vmax
specific 
activity Km/Vmax
Modified HexB 1.5 × 10−2 1.1/1.5 × 10−2 5.0 × 10−2 0.6/6.7 × 10−3
WTHexB 3.3 × 10−3 1.1/3.3 × 10−3 5.0 × 10−5 5.5/6.7 × 10−5
WTHexA 1.0 × 10−2 1.7/1.2 × 10−2 8.3 × 10−3 1.3/3.3 × 10−3
Abbreviations:  4-MUG,  4-methylumbelliferyl  N-acetyl-β-D-glucosaminide; 
4-MUGS,  4-methylumbellifery-6-sulfo-β-D-glucosaminide  potassium  salt;  Hex, 
β-hexosaminidase; WT, wild type.
Specific activity: (mmol/minute/mg protein); Km: (mmol/l); Vmax: (mmol/minute/
mg protein).
table 2  Analysis of enzyme thermostability in plasma
enzyme
residual activity
2 days 7 days
WTHexA 47.7 27.0
WTHexB 94.3 85.3
Modified HexB 96.6 91.4
Abbreviations: Hex, β-hexosaminidase; WT, wild type.
Means indicate percent of starting enzyme activity in mice plasma. Values indicate 
percentages of starting enzyme activity in the presence of murine plasma.1020  www.moleculartherapy.org  vol. 19 no. 6 june 2011     
© The American Society of Gene & Cell Therapy
ERT Involving Modified Human HexB for Tay-Sachs Disease
after injection. In the brains of SD mice treated with phosphate-
buffered saline (PBS) as a control, marked GM2 accumulation 
was  observed  throughout  the  brain  regions  (Figure  4bA–D). 
In contrast, on treatment with the modified HexB, remarkable 
reductions of GM2 were observed in the thalamus and cerebral 
cortex  (Figure  4bE,F),  although  it  was  less  in  the  cerebellum 
(Figure 4bG,H).
To  characterize  the  glycosphingolipids  (GSLs)  in  the  SD 
mice brains after the modified HexB treatment, thin-layer chro-
matography  analysis  was  performed  (Figure  4c  and  Table  3). 
Excessively  accumulated  GM2  and  GA2  due  to  the  deficiency 
of HexA activity were observed in the brains of SD mice. In the 
modified HexB-treated group, the levels of GM2 and GA2 in the 
brain had markedly decreased 1 week after injection, lower lev-
els being maintained, compared to in control mice, for 3 weeks 
after injection. These results indicated that the modified HexB can 
degrade the accumulated substrates in vivo. We also examined 
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Figure 3  degradation of GM2 by modified HexB in the presence of 
a detergent. (a) Five micrograms of GM2 was incubated with wild-type 
HexA (WTHexA), WTHexB and the modified HexB, respectively, in the 
presence or absence of 2 mmol/l taurodeoxycholate hydrate (−, absence; 
+, presence), and the GSLs were purified and subjected to thin-layer 
chromatography (TLC). The TLC plate was sprayed with orcinol reagent. 
(b) The uptake of enzymes by fibroblasts was analyzed as described 
under “Materials and Methods.” Before enzyme treatment, fibroblasts 
were treated (+) or not treated (−) with 5 mmol/l M6P. Error bars rep-
resent means ± SD (n = 4) (**P < 0.01). (c) Cultured fibroblasts derived 
from the Tay-Sachs disease (TSD) patient were treated with WTHexA, 
WTHexB and the modified HexB, and then immunostaining for GM2 
was performed as described under “Materials and Methods.”
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Figure  4  Hex  activity  and  accumulated  Gsl  level  in  brains  from 
sandhoff disease (sd) (Hexb−/−) model mice treated with a single 
administration of the modified HexB. The modified HexB was adminis-
tered (20,000 nmol/hour/25 µl) to the lateral ventricle of Hexb−/− mice, 
and then the mice were killed after 1 and 3 weeks after administration. 
(a) The Hex activity in an extract of each brain part (fore-, mid-, and hind-
brain, respectively) of Hexb−/− mice was measured. Error bars represent 
means ± SD (n = 3) (*P < 0.05, **P < 0.01). (b) Immunohistochemical 
analysis of the accumulated GM2 in the brains of Hexb−/− mice was per-
formed 3 weeks after administration of modified HexB was performed, 
and then counter-stained with hematoxylin. (c) Thin-layer chromatog-
raphy analysis of GSLs was performed 1 week after administration of the 
modified HexB. PBS, phosphate-buffered saline; SD, Sandhoff disease; 
WT, wild type.Molecular Therapy  vol. 19 no. 6 june 2011  1021
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whether icv administered modified HexB distribute to periphery 
or not. One week after injection, the 4-MUGS-degrading activity 
in the liver of SD mice treated with modified HexB significantly 
increased to 363 ± 108.4 % of that of WT mice (Supplementary 
Figure S2a), and the levels of GM2 and GA2 in the liver had mark-
edly decreased (Supplementary Figure S2b and Supplementary 
Table S2). These finding suggested that icv administration is effec-
tive for reducing the accumulated GSL levels not only in the brain, 
but also in the peripheral organs.
dIscussIon
ERT is a clinically available treatment for LSDs involving visceral 
manifestations. However, it has several disadvantages, including 
high-frequency of administration, ineffectiveness for LSDs involv-
ing neurological symptoms and the production of neutralizing 
antibodies in LSD patients because of the continuous administra-
tion of relatively high doses of the enzyme drugs at above 1 mg 
protein/injection.17
In order to develop a novel therapeutic enzyme for overcom-
ing the disadvantages of the present one, we performed the drug 
design of a genetically engineered human HexB for the future 
ERT for TSD and SD in this study. First, we designed a modified 
Hex β-subunit with partial amino acid substitutions compared to 
in the α-subunit on the basis of homology modeling. It was pre-
dicted that βD452 and βL453 should be changed to αN423 and 
αR424, to alter the substrate specificity, respectively, as well as 
the βRQNK (312-315) sequence corresponding to αGSEP (280-
283), to introduce the α-specific loop structure for binding as to 
GM2AP into the β-subunit.
It was reported previously that αN423 and αR424 stabilize not 
only the negatively charged sialic acid moieties of GM2 but also 
neutral substrates,18,19 and mutant HexA without the loop struc-
ture of αGSEP (280-283) exhibits no GM2-degrading ability in 
TSD fibroblasts because HexA can degrade GM2 through binding 
with GM2AP via the loop sequence specific for the α-subunit.20
Here, we demonstrated that the modified HexB produced by 
a CHO cell line stably expressing the engineered HEXB encoding 
the human Hex β-subunit bearing with the amino acid substitu-
tions (R312G, Q313S, N314E, P315K, D452N, and L453R) had 
acquired the catalytic activities toward 4-MUGS and GM2 in vitro 
in the presence of a detergent. The modified HexB was also effi-
ciently taken up by fibroblasts derived from a TSD patient via 
CI-M6PR and degraded the GM2 accumulated in lysosomes as the 
result that the incorporated enzyme could interact with GM2AP. 
On icv administration to SD model mouse, it was successfully 
incorporated into the brain parenchyma, restored the Hex activity, 
and cleaved the GM2 and GA2 accumulated in neural cells.
Recent experimental and clinical attempts to develop icv and 
intrathecal ERTs for LSDs with neurological manifestations14–16 
are  expected  to  lead  to  central  nervous  system–directed  ERTs 
using the CI-M6PR expressed on neural cells as a delivery target 
molecule that can be clinically applied for these diseases in the 
near future. The present modified HexB has several advantages 
for the future ERT for TSD and SD. First, it has HexA-like GM2-
degrading activity to reduce the GM2 accumulated in the brain 
parenchyma on icv administration to SD mice. The icv ERT is 
also expected to have therapeutic effects on TSD and SD patients 
involving neurological symptoms.
Second,  modified  HexB  is  considered  to  be  superior  to 
WTHexA as for uptake by target cells expressing CI-M6PR on 
their cell surface because homodimeric HexB should have four 
M6P-carrying N-glycans per molecule whereas the heterodimeric 
WTHexA should have three. It was reported that the human Hex 
β-subunit contains two N-glycans carrying M6P but the α-subunit 
only contains one.21 Akeboshi et al. reported that a higher num-
ber of M6P residues on N-glycans of a recombinant human HexA 
derived from a methylotrophic yeast Ogataea minuta strain causes 
more efficient uptake of the enzyme into TSD and SD cells, lead-
ing  to  improvement  of  the  replacement  effect.22  These  studies 
suggested that the number of M6P-type-N-glycans attached to a 
replacement enzyme contributes to the efficiency of uptake and 
the therapeutic effectiveness. Consistent with this evidence, we 
also demonstrated the more efficient uptake of the modified HexB 
by TSD fibroblasts and neural cells in the brain parenchyma of SD 
mice and recovery of Hex activity in comparison with WTHexA.
Third, the modified HexB retained extremely high stability at 
37 °C in the presence of plasma similar to WTHexB, and main-
tained high Hex activity in the brains of Hexb−/− mouse during 
3 weeks after icv injection. These enzymatic characters are also 
advantageous as to not only stable industrial production of the 
recombinant  enzyme  drug  but  also  stability  in  the  circulation 
system and in intracellular of the patient after administration. 
Previously,  we  founded  that  intracerebroventricularly  adminis-
tered enzyme can distribute to peripheral organs (data not shown). 
In fact, the modified HexB administered intracerebroventricularly 
to SD mouse distributed to periphery, and incorporated into the 
liver and then reduced the accumulated GSL levels. These evi-
dences suggest that the modified HexB excreted from the CSF on 
icv ERT should contribute to recover the Hex activities in the vis-
ceral organs and ameliorate the peripheral manifestations.
Recently, it has become more important to avoid the immune 
response  caused  by  repetitive  administration  of  therapeutic 
enzymes on continuous intravenous ERT. In the case of Fabry dis-
ease, the clinical demand for an application of ERT for patients has 
been increasing, however, repeated administration of recombinant 
α-galactosidase to patients cause infusion reactions, mainly an 
allergic one, because most male Fabry disease patients do not have 
table 3  comparison of the relative level of Gsls in the brain present 
in mouse brain
Gsl PBs-treated control Modified HexB-treated
GM2
  Cerebrum 1.00 0.77 ± 0.02**
  Cerebellum 1.00 0.57 ± 0.04*
GA2
  Cerebrum 1.00 0.66 ± 0.04**
  Cerebellum 1.00 0.48 ± 0.04**
Abbreviations:  HexB,  β-hexosaminidase  B;  PBS,  phosphate-buffered  saline; 
SD, Sandhoff disease; TLC, thin-layer chromatography.
The relative levels of GM2 and GA2 extracted from mouse brains after enzyme 
treatment were determined by TLC. These values were calculated from the ratio 
of the band intensities on TLC and normalized on the basis of those for SD mice 
treated with PBS as controls. Mean ± SD.
**P < 0.001: PBS versus modified HexB, *P < 0.05: PBS versus modified HexB.1022  www.moleculartherapy.org  vol. 19 no. 6 june 2011     
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any α-galactosidase protein.9,23 The induction of immune toler-
ance using an immunosuppressive regimen, cyclosporine and aza-
thiopurine, improves the effectiveness of a recombinant enzyme,24 
although these reagents have side effects. From these aspects, we 
would like to propose and emphasize the clinical use of modified 
HexB instead of WTHexA to avoid the immune response to HexA 
containing α-subunit for future ERT for TSD patients who have 
the endogenous WTHexB. The evidence we obtained in this study 
suggests that the modified HexB should be clinically advantageous 
as a novel therapeutic enzyme, and that low-immunogenic icv and 
intravenous ERTs for TSD patients can be expected in the future.
MAterIAls And MetHods
Materials.  4-MUG,  M6P,  nutrient  mixture  Ham’s  F-10,  EX-CELL  ACF 
CHO  Medium,  dimethyl  sulfoxide,  BCIP/NBT  liquid  substrate  system 
and bovine serum albumin were purchased from Sigma (St Louis, MO). 
GenomeLab  DCIT-Quick  Start  Kit,  CEQ  Separation  Gel-LPAI  and 
CEQ  separation  buffer  were  purchased  from  Beckman  Coulter  (North 
Harbor, CA). Wizard plus midipreps DNA purification kit, dNTPs, and 
hygromycin  were  purchased  from  Promega  (Madison,  WI).  PepstatinA 
and  leupeptin  were  purchased  from  Peptide  Institute  (Osaka,  Japan). 
Quick gel extraction kit and purification kit were purchased from QIAGEN 
(Germantown, MA). 4-MUGS was purchased from Calbiochem (San Diego, 
CA). Fetal bovine serum was from Biological Industry (Tokyo, Japan). KOD 
plus polymerase was from TOYOBO (Osaka, Japan). DNA ligation kit ver. 
1 was purchased from TaKaRa (Otsu, Japan). G418 was purchased from 
Wako (Osaka, Japan). Unifecter was purchased from B-Bridge International 
(Mountain View, CA). DC protein assay kit was purchased from Bio-Rad 
(Hercules, CA). Viva pure mini spin column Q type was purchased from 
VIVA  SCIENCE  (Stonehouse,  UK).  Amicon  ultra  was  purchased  from 
Millipore  (Carrigtwohill,  Ireland).  HiTrap  DEAE  HP,  Phenyl  HP  and 
Concavalin A-Sepharose were purchased from GE Healthcare BioSciences 
(Piscataway, NJ and Uppsala, Sweden, respectively).
Mice. Sandhoff (Hexb−/−) mice (C57BL/6x129sv) were kindly provided by 
Dr Proia (National Institutes of Health). Mice were bred by mating with 
WT C57BL/6 mice (SLC, Shimazu, Japan), and were housed under stan-
dard housing conditions approval of the Animal Care Committee of the 
University of Tokushima.
Cells. Cultured skin fibroblasts from a patient with TSD (F218), and a nor-
mal control subject (F592) were obtained with informed consent, and the 
study was approved by the ethical committee of our institution. The fibro-
blasts were cultured in Ham’s F-10 medium containing 10% fetal bovine 
serum and antibiotics at 37 °C in a humidified incubator continuously 
flushed with a mixture of 5% CO2–95% air.
Antibodies. Mouse monoclonal antibodies were kindly donated by Dr Tai 
(Department of Tumor Immunity, The Tokyo Metropolitan Institute of 
Medical science, Tokyo, Japan); GMB28 (anti-GM2; immunoglobulin M) 
against GM2.
Design of a modified human Hex β-subunit.To determine the amino acid 
residues comprising the active site pocket of the Hex β-subunit, the sol-
vent accessible surface area value of each amino acid residue was calculated 
both in the apo form of Hex β-subunit and its complex with the substrate 
analog inhibitor. Then, the amino acid residues whose solvent accessible 
surface area values decrease from the apo form to the complex are defined 
as amino acid residues comprising the pocket. The calculations were con-
ducted using the program ACCESS,25 which is an implementation of the 
Lee and Richards algorithm.26 The three-dimensional coordinates of the 
human Hex β-subunit was obtained from the Protein Data Bank (protein 
Databank code: 1now).27
To  explore  the  difference  between  the  Hex  α-  and  β-subunits, 
comparison of their protein sequences was performed using BLAST.28 The 
protein sequences of the Hex α- and β-subunits were obtained from the 
ExPASy Homepage (http://au.expasy.org/).
Structural  modeling  of  a  modified  Hex  β-subunit  was  performed 
using  molecular  modeling  software  TINKER.29–32  Again,  the  crystal 
structure of the Hex β-subunit (protein Databank code: 1now) was used 
as a template. Then, energy minimization was performed and the root-
mean-square gradient value was set at 0.05 kcal/mol/Å.
Construction of a vector plasmid and establishment of CHO cell lines 
  stably expressing the modified HEXB. DNA fragments 1, 2, and 3 were 
amplified using primer sets as summarized in Supplementary Table S1, and 
the pCXN2-HEXB-Neo vector previously constructed in our laboratory,33 
as a template, under the conditions indicated in Supplementary Table S1. 
Fragments 4 and 5 were amplified using sets of amplified fragments (frag-
ment 1 and 2, and 2 and 3, respectively) as templates by two-step PCR.
Fragment 5 was digested with BamHI and BglII, and then ligated into 
a pFLAG-CMV2-Neo derivative digested with the same endonucleases. 
The resultant vector plasmid was designated as pFLAG-CMV2-modified 
HEXB-Neo. Fragment 4 was digested with BamHI and XhoI, and then 
ligated into pFLAG-CMV2-modified HEXB-Neo digested with the same 
endonucleases. The resultant vector plasmid was digested with XhoI and 
BglII, and then ligated into the pCXN2-Neo vector digested with the same 
endonucleases. The resultant vector plasmid was designated as pCXN2-
modified HEXB-Neo.
One day before transfection, seed 2.0–4.0 × 105 cells per φ 60 mm dish 
in 2 ml of Ham’s F-10 without antibiotics to attain 80–90 % confluence at a 
time of transfection. For a transfection sample, prepare DNA-Lipofectamine 
2000 complexes as follows: dilute 4 µg DNA and 20 µg Lipofectamine 2000 
in 250 µl Ham’s F-10 without serum, respectively, and mix gently and 
then let for 20 minutes at room temperature. Cells washed with serum-
free medium, added 1.5 ml of medium and then added 500 µl of DNA-
Lipofectamine 2000 complexes. Incubate the cells at 37 °C in a humidified 
incubator with 5% CO2 for 24 hours and add 2 ml of medium containing 
serum. Neomycin-resistant cell lines were selected by the limited dilution 
method, and designated as CHO/modified HEXB cell lines.
Purification  of  recombinant  Hex  isozymes. Each CHO cell line stably 
expressing  and  secreting  the  WTHexA,  WTHexB,  or  modified  HexB, 
respectively, was cultured in EX-CELL ACF CHO medium in an incubator 
containing 5% CO2. CM derived from each cell line was collected. For acid 
precipitation, HCl added and adjusted to pH 4.5 and gently rotated at 4 °C 
for 2 hours and then centrifuged at 6,000g for 30 minutes at 4 °C. The resul-
tant supernatant corrected and NaOH added to a final pH at pH 7.0. For 
lectin affinity chromatography, CaCl2 and MnCl2 were added to the final 
concentrations of 1 mmol/l. CM was applied to a Concavalin A-Sepharose 
column  equilibrated  with  1 mmol/l  CaCl2/1 mmol/l  MnCl2/20 mmol/l 
HEPES (pH 7.2) (HEPESB). After washing the column with 50 column 
volumes of 0.5 mol/l NaCl/HEPESB, the bound proteins were eluted with 
0.5 mol/l  methyl  α-D-mannopyranoside/0.1 mol/l  NaCl/HEPESB.  The 
eluate containing Hex activity as collected, and then (NH4)2SO4 was added 
to a final concentration of 1 mol/l. The eluate containing Hex activity was 
applied to a HiTrap Phenyl HP column. Bound proteins were eluted by 
increasing the proportion of sodium phosphate buffer (NaPB). The eluate 
containing Hex activity was applied to a HiTrap DEAE HP column. Flow-
through fractions containing WTHexB and modified HexB, and elution 
fractions containing WTHexA were collected. The eluate containing Hex 
activity was collected and dialyzed against PBS (pH 7.4), and then concen-
trated with Amicon ultra (30,000 MWCO; Millipore, Billerica, MA). The 
purified Hex isozymes were stored at −80 °C before use.
Characterization  of  recombinant  Hex  isozymes  and  analysis  of  pro-
cessing  of  the  β-subunit.  The  cultured  CHO  cell  line  stably  express-
ing the modified Hex β-subunit gene on φ 60 mm dishes were grown to Molecular Therapy  vol. 19 no. 6 june 2011  1023
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confluency. After washing with PBS, they were harvested, and then sus-
pended in 10 mmol/l NaPB containing protease inhibitors. The cell sus-
pensions were sonicated, and then centrifuged at 13,200g for 15 minutes 
at 4 °C, the resultant supernatants being stored as cell extracts. To char-
acterize the intracellular and secreted Hex isozymes, aliquots of the cell 
extracts and CM were subjected to native-PAGE on a 7.5% acrylamide 
gel. To analyze the intracellular processing of the β-subunit, aliquots of 
HexB fractions of cell extracts were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, on a 10% acrylamide gel. The proteins 
were transferred to polyvinylidine difluoride membranes. On immuno-
blotting, each membrane was incubated with 50% (v/v) Blocking One 
(Nacalai Tesque, Japan) in Tris-buffered saline (pH 7.4) overnight at 4 °C. 
The membrane was treated with anti-human HexA polyclonal antibodies33 
diluted with Blocking One/Tris-buffered saline (1:1,000 dilution) at room 
temperature. After washing, biotin-conjugated anti-rabbit immunoglobu-
lin G antibody (1:1,000 dilution) was used as secondary antibodies. After 
washing, the membrane was treated with alkaline phosphatase-conjugated 
streptavidin (1:1,000 dilution) for 1 hour. The protein bands were visu-
alized with the BCIP/NBT liquid substrate kit system. A kinetic experi-
ment was performed with the modified HexB to determine the Vmax and Km 
  values using human WTHexA and WTHexB as controls.
In  vitro  stability  of  the  modified  HexB.  Each  enzyme  was  added  to 
10 mmol/l NaPB (pH 6.0) containing 30% murine plasma, followed by 
incubation at 37 °C. Taking the Hex activity at time 0 as 100%, the stabili-
ties of each enzyme was calculated as the ratio (%) of the enzyme activity 
at the incubation time point to the value at time zero.
Degradation of GM2 in vitro by modified HexB. Micellar form of GM2 
was incubated with each Hex isozyme (modified HexB and WTHexA: 3,000 
nmol/hour 4-MUGS-degrading activity/well; WTHexB: 3,200 nmol/hour 
4-MUG-degrading activity/well, respectively) in the presence or absence of 
2 mmol/l sodium taurodeoxycholate hydrate in 200 µl of 10 mmol/l citrate 
buffer (pH 4.2) at 37 °C for 24 hours. After the incubation, the reaction was 
stopped by heating the tube in a bath of boiling water for 3 minutes, GSLs 
were isolated using a C18 Sep-Pak Cartridge. Aliquots of samples were 
spotted on a Silica gel plate and developed with chloroform/methanol/0.2 
% CaCl2 (60:40:90 (v/v)). To reveal GSLs, the thin-layer chromatography 
plate was sprayed with orcinol reagent and heated at 120 °C for 5 minutes.
Assay  for  enzyme  replacement  effects  of  the  modified  HexB  on  TSD 
  fibroblasts. A fibroblastic cell strain (F218) from a TSD patient was seeded 
onto a type I collagen-coated 96-well plate (2 × 103 cells/well), and then 
the isolated WT-, modified HexB and WTHexA fractions derived from 
CM  (modified  HexB  and  WTHexA:  4-MUG-degrading  activity  1,500 
nmol/hour/well; WTHexB: 4-MUG-degrading activity 3,200 nmol/hour/
well, respectively) were added, and followed by incubation for 3 days. The 
medium was removed, and the cells were washed with PBS and then treated 
with NaPB containing 1% NP-40/protease inhibitors. The microplate was 
vibrated on an EM-36 Micro Mixer for 1 hour at 4 °C, following pipetting, 
and then the intracellular activities were assayed. In some experiments, M6P 
was added to a final concentration of 5 mmol/l, and followed by incubation 
for 1 hour prior to the addition of an enzyme fraction. The TSD (F218) 
cells were seeded onto a type I collagen-coated 96-well plate (3 × 103 cells/
well), and then the isolated WTHexB, modified HexB and WTHexA frac-
tions derived from CM (modified HexB and WTHexA: 1,500 nmol/hour 
4-MUG-degrading  activity/well;  WTHexB:  3,200  nmol/hour  4-MUG-
degrading activity/well, respectively) were added, and followed by incuba-
tion for 3 days. F218 cells were seeded onto 8-well Lab-Tek chamber slides 
(Nunc, Rochester, NY). After administration of the WTHexB, modified 
HexB and WTHexA fractions to the cultured media, the fibroblasts were 
incubated for 3 days and then fixed with cold 4% paraformaldehyde. After 
washing with PBS, intracellular GM2 was detected by anti-GM2 mouse 
monoclonal antibodies according to the method described previously.34 
The specimens were viewed under a confocal fluorescent microscope.
Enzyme assays. Hex isozyme activities in cell extracts and CM toward 
4-MUG and 4-MUGS were measured in 30 µl of 0.1 mol/l sodium citrate 
buffer (pH 4.5 and 4.2, respectively) by incubation at 37 °C for 30 minutes 
followed by addition of 375 µl of a 0.2 mol/l glycine-NaOH (pH 10.7). Km 
and Vmax value were determined by the method of Lineweaver and Burk 
plot at various substrate concentrations (4-MUG, 0.0625–2 mmol/l and 
4-MUGS,  0.0625–4 mmol/l,  respectively).35  Protein  levels  were  assayed 
with the Dc protein assay kit with bovine serum albumin as a standard.
Intracerebroventricular administration of recombinant modified HexB 
and analysis of the enzyme replacement effect. SD mice at the age of 
10 weeks were anesthetized with sodium 5-ethyl-5-(1-methylbuthyl) bar-
biturate  (32.4 mg/kg  body  weight).  Modified  HexB  (20,000  nmol/hour 
4-MUG-degrading activity/25 µl) as well as PBS, as an enzyme-untreated 
control, in a total volume of 25 µl, were injected (0.5 mm caudally from the 
bregma, 1.0 mm laterally from the central line, and 2.0 mm from the top 
of the skull) into each ventricle with a two-step needle attached to a glass 
syringe. After the injection, the needle was held at the site for 1 minute to 
prevent reverse flow. One and three weeks after injection, Hexb−/− mice 
were killed, and their brains and livers were obtained after PBS perfusion. 
The brains were cut into three sections (fore-, mid-, and hindbrain, respec-
tively). The sections were homogenized by sonication in 10 mmol/l NaPB 
containing protease inhibitors. After centrifugation at 13,200g, the super-
natants were collected as tissue extracts. For immunohistochemical analy-
sis, each brain hemisphere was embedded in O.C.T. compound and frozen 
at −30 °C. Slices (10 µm thick) were prepared with a cryostat, placed on 
silane-coated glass slides, and then air-dried for 2 hours. The brain slices 
were fixed with 4% paraformaldehyde/PBS for 2 days at 4 °C. After washing 
with PBS, the specimens were treated with 0.03% H2O2/PBS and washed 
with PBS. They were then treated with GMB28 mouse monoclonal anti-
bodies diluted with 5% goat serum/1% bovine serum albumin/PBS (1:20 
dilution) overnight at 4 °C. After washing with 0.05% Tween20/PBS, the 
brain slices were treated with anti-mouse immunoglobulin M antibodies 
diluted with 5% goat serum/1% bovine serum albumin/PBS (1:1,000 dilu-
tion) for 1 hour at room temperature. After washing, the brain slices were 
treated with horseradish peroxidase-conjugated streptavidin for 30 min-
utes at room temperature. After washing, the immuno-positive cells were 
visualized with diaminobenzidine (DAB) reagent (0.012% H2O2/0.0133% 
DAB/50 mmol/l Tris-HCl pH 8.0). The specimens were counter-stained 
with hematoxylin.
Analysis  of  the  glycosphingolipid  accumulated  in  mouse  brains  and 
  livers by thin-layer chromatography. The extraction of glycolipids was 
performed as previously described.36 For determination of GSL pattern, 
the silica gel plate was heated at 120 °C for 30 minutes on the hot plate 
before sample spotting. Aliquots of samples were spotted on a silica gel 
plate  and  developed  with  chloroform/methanol/0.2%  CaCl2  (55:45:10 
(v/v)) for 50 minutes. To reveal GSLs, the silica gel plate was sprayed with 
orcinol reagent and heated at 120 °C for 5 minutes on the hot plate.
Statistical analysis was performed using Turkey’s post hoc test.
suPPleMentArY MAterIAl
Figure S1.  Hex activity in the brain from SD mice treated with a sin-
gle administration of enzymes.
Figure S2.  Hex activity and accumulated GSL level in the liver from 
SD mice treated with a single administration of the modified HexB.
Table S1.  Primer sets and PCR conditions.
Table S2.  The relative levels of GM2 and GA2 extracted from mouse 
livers after enzyme treatment were determined by TLC.
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